ImmunityBio (IBRX) News Today $4.49 -0.38 (-7.80%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period ImmunityBio Reports Third-Quarter 2024 Financial ResultsNovember 12, 2024 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Stock Price Down 5.3% - Time to Sell?ImmunityBio (NASDAQ:IBRX) Shares Down 5.3% - Here's What HappenedNovember 4, 2024 | marketbeat.comPenny Stock Trades: Joby Aviation and ImmunityBioOctober 31, 2024 | baystreet.caIMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 30, 2024 | globenewswire.comImmunityBio (NASDAQ:IBRX) Stock Price Down 9.6% - Here's WhyImmunityBio (NASDAQ:IBRX) Stock Price Down 9.6% - Time to Sell?October 29, 2024 | marketbeat.comImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025October 28, 2024 | seekingalpha.comImmunityBio: 1st patient dosed in CAR-NK cell therapy study relapsed NHLOctober 25, 2024 | markets.businessinsider.comImmunityBio Inc. IBRX (U.S.: Nasdaq)October 25, 2024 | wsj.comImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?October 25, 2024 | finance.yahoo.comImmunityBio extends gains after trial updateOctober 25, 2024 | msn.comImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be CarefulOctober 25, 2024 | seekingalpha.comImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading Volume - Time to Buy?ImmunityBio (NASDAQ:IBRX) Sees Large Volume Increase - Here's What HappenedOctober 25, 2024 | marketbeat.comTraders Buy Large Volume of ImmunityBio Call Options (NASDAQ:IBRX)ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) saw some unusual options trading activity on Friday. Traders purchased 9,749 call options on the company. This represents an increase of 125% compared to the typical volume of 4,330 call options.October 25, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading 7.8% Higher - Here's WhyImmunityBio (NASDAQ:IBRX) Shares Up 7.8% - Time to Buy?October 24, 2024 | marketbeat.comFirst Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin LymphomaOctober 24, 2024 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Upgraded to Strong-Buy by EF Hutton Acquisition Co. IEF Hutton Acquisition Co. I raised ImmunityBio to a "strong-buy" rating in a research report on Wednesday.October 24, 2024 | marketbeat.comEF Hutton Initiates Coverage of ImmunityBio (IBRX) with Buy RecommendationOctober 24, 2024 | msn.comImmunityBio initiated with a Buy at EF HuttonOctober 23, 2024 | markets.businessinsider.com800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBioOctober 23, 2024 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Should You Buy?ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Still a Buy?October 23, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 6.2% - Time to Buy?ImmunityBio (NASDAQ:IBRX) Stock Price Up 6.2% - Here's WhyOctober 11, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Down 4.5% - Time to Sell?ImmunityBio (NASDAQ:IBRX) Stock Price Down 4.5% - Here's WhyOctober 9, 2024 | marketbeat.comImmunityBio: Moving The NeedleOctober 7, 2024 | seekingalpha.comMore layoffs for ImmunityBio's Dunkirk facilityOctober 2, 2024 | bizjournals.comBluebird Bio To Reduce Approx. 25% Of Its Workforce - Quick FactsSeptember 24, 2024 | markets.businessinsider.comImmunityBio (NASDAQ:IBRX) Trading Down 3.2%ImmunityBio (NASDAQ:IBRX) Stock Price Down 3.2%September 17, 2024 | marketbeat.comBank of New York Mellon Corp Has $3.93 Million Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)Bank of New York Mellon Corp boosted its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 37.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 621,536 shares of the company's stockSeptember 15, 2024 | marketbeat.comImmunitybio Inc. (IBRX): Fast-Growing Penny Stock To ConsiderSeptember 12, 2024 | msn.comImmunityBio reports extended survival in NSCLC therapy trialSeptember 11, 2024 | uk.investing.comImmunityBio (NASDAQ:IBRX) Stock Price Up 6.8%ImmunityBio (NASDAQ:IBRX) Trading 6.8% HigherSeptember 9, 2024 | marketbeat.comShort Interest in ImmunityBio, Inc. (NASDAQ:IBRX) Grows By 5.2%ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 49,180,000 shares, a growth of 5.2% from the July 31st total of 46,770,000 shares. Based on an average daily volume of 3,240,000 shares, the short-interest ratio is currently 15.2 days. Approximately 31.6% of the company's shares are short sold.September 3, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 3.7%ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.7%August 30, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 7.8%ImmunityBio (NASDAQ:IBRX) Stock Price Up 7.8%August 21, 2024 | marketbeat.comPiper Sandler Keeps Their Hold Rating on ImmunityBio (IBRX)August 19, 2024 | markets.businessinsider.comImmunityBio (NASDAQ:IBRX) PT Lowered to $4.75 at Piper SandlerPiper Sandler lowered their price objective on shares of ImmunityBio from $6.00 to $4.75 and set a "neutral" rating for the company in a report on Monday.August 19, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Shares Down 6% ImmunityBio (NASDAQ:IBRX) Trading Down 6%August 19, 2024 | marketbeat.comImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me CautiousAugust 19, 2024 | seekingalpha.comABSI Sep 2024 6.000 callAugust 13, 2024 | ca.finance.yahoo.comCompany News for Aug 13, 2024August 13, 2024 | msn.comImmunityBio (NASDAQ:IBRX) Shares Down 2.7% After Earnings MissImmunityBio (NASDAQ:IBRX) Shares Down 2.7% on Disappointing EarningsAugust 13, 2024 | marketbeat.comImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA ApprovalAugust 12, 2024 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Stock Price Up 6.9%ImmunityBio (NASDAQ:IBRX) Stock Price Up 6.9%August 9, 2024 | marketbeat.comImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial CancerAugust 6, 2024 | finance.yahoo.comImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Vanguard Group Inc.Vanguard Group Inc. raised its holdings in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 1.6% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 13,539,590 shares of the company's stock after purchasingAugust 6, 2024 | marketbeat.comIBRX Aug 2024 4.000 put (IBRX240809P00004000)August 5, 2024 | finance.yahoo.comIBRX Aug 2024 6.500 call (IBRX240809C00006500)August 5, 2024 | finance.yahoo.comKuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law FirmJuly 25, 2024 | prnewswire.comHealthcare Services Group is about to announce its earnings — here's what to expectJuly 23, 2024 | markets.businessinsider.com7 Biotech Stocks to Keep on Your Clinical RadarJuly 23, 2024 | investorplace.comImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Blair William & Co. ILBlair William & Co. IL raised its stake in ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 106.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 313,542 shares of the company's stock after buying an additional 161,530 shares durJuly 22, 2024 | marketbeat.com Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address 📉 Warning: Market Crash Predicted - Secure Your Savings (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%. Take these 4 steps to protect your retirement here >>> IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.970.56▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼33▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IOVA News VCYT News HRMY News BCRX News SANA News EBS News FLGT News ALEC News SAGE News ITOS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBRX Stock Alerts